Inclusion Criteria:

Here's a concise English translation:

- Voluntarily signed informed consent to participate in a non-interventional study.

- Hospitalized patients with moderate COVID-19 requiring anticoagulant therapy for
prevention of thrombotic complications.

- Men and women aged ≥18 years.

- Patients prescribed Dimolegin® 10 mg enteric-coated film tablets for
thromboprophylaxis as part of routine care for moderate COVID-19.

- Ability to understand study requirements, provide written consent and comply with
protocol procedures.

Exclusion Criteria:

- Hypersensitivity to Dimolegin®.

- Clinically significant active bleeding at screening.

- Concomitant therapy with fibrinolytics or other anticoagulants.

- Anemia or thrombocytopenia.

- Thrombophilia.

- Other coagulopathies or contraindications to anticoagulants.

- Liver disease with impaired function or biliary tract disease.

- Creatinine clearance <30 mL/min.

- Gastrointestinal disorders affecting absorption.

- Pregnancy, breastfeeding, suspected pregnancy, or planned pregnancy within 3 months
(including male patients whose partners plan pregnancy).

- Use of investigational or unapproved drugs, or participation in another clinical
study within 90 days before therapy start.

- History or suspicion of alcohol or drug abuse, dependence, or addiction.

- Any other condition that, in the investigator's opinion, could interfere with study
participation or pose undue risk.